What are the pulmonary toxicities associated with Keytruda (pembrolizumab) and how should they be monitored and managed?

Pulmonary Toxicities of Keytruda (Pembrolizumab)

Pneumonitis is the primary and most serious pulmonary complication of pembrolizumab, occurring in 3-4% of patients across all cancer types, with fatal outcomes accounting for 35% of all PD-1/PD-L1-related deaths. 1, 2

Incidence and Risk Stratification

The overall incidence varies significantly by patient population and clinical context:

• Standard risk patients: 2.7% all-grade pneumonitis, 0.8% grade 3+ pneumonitis across cancer types 1
• NSCLC patients: 3.8% overall incidence with pembrolizumab monotherapy 1
• High-risk populations requiring heightened surveillance include:
  • Prior thoracic radiation: 6.0% incidence 1
  • Underlying asthma or COPD: 5.3% incidence 1
  • NSCLC and renal cell carcinoma patients (higher than melanoma) 1
  • Male patients and current/former smokers 1
  • Squamous cell histology with high PD-L1 expression 3

The median time to onset is 2.1 months in lung cancer patients versus 5.2 months in melanoma patients, emphasizing the need for early vigilance in thoracic malignancies. 1

Clinical Presentation

Patients present with a spectrum of respiratory symptoms, though 20% may be asymptomatic and detected only on imaging. 4

Common symptoms include: 1

• Dry cough (most common)
• Progressive dyspnea
• Fatigue
• Chest pain
• Fever

Critical pitfall: Do not attribute new respiratory symptoms to disease progression without excluding pneumonitis, as this delay can be fatal. 5

Radiographic Patterns and Severity Correlation

The CT pattern directly correlates with toxicity grade and prognosis: 1

• Organizing pneumonia (OP) pattern (23% of cases): Patchy consolidation, ground-glass opacities, and nodules 5, 1
• Hypersensitivity pneumonitis (HP) pattern (16% of cases): Ground-glass opacities with centrilobular nodules 1
• Nonspecific interstitial pneumonia (NSIP) pattern: Lower toxicity grades 1
• Diffuse alveolar damage (DAD) pattern: Highest grades and worst prognosis 5, 1

The DAD pattern carries the highest mortality risk and requires immediate aggressive intervention. 1

Diagnostic Algorithm

When pneumonitis is suspected, execute this stepwise approach:

1. Immediately obtain high-resolution chest CT with contrast to identify the radiographic pattern and exclude alternative diagnoses 5

2. Establish temporal correlation with pembrolizumab administration (typically within first 3-6 months) 1, 6

3. Exclude infectious causes through:

   • Bronchoalveolar lavage with comprehensive cultures (bacterial, fungal, viral, acid-fast bacilli) 5, 7
   • Blood and urine cultures if clinically indicated 5
   • Serologic testing for atypical pathogens 8

4. Rule out other etiologies:

   • Tumor progression 5
   • Pulmonary embolism 5
   • Cardiac events (heart failure, myocarditis) 5
   • Pleural carcinomatosis 5

5. Consider pulmonary function tests if CT is negative but clinical suspicion remains high 5

Do not delay treatment while awaiting biopsy results if clinical and radiographic findings strongly suggest pneumonitis. 5

Management by Grade

The FDA label mandates monitoring and grade-based intervention: 2

Grade 1 (Asymptomatic, radiographic findings only):

• Withhold pembrolizumab 5
• Monitor closely with serial imaging 5
• May resume if resolves to baseline 5

Grade 2 (Symptomatic, not interfering with ADLs):

• Withhold pembrolizumab 5, 2
• Initiate prednisone 1 mg/kg/day (or equivalent) 5
• Taper over 4-6 weeks after improvement to grade <1 5
• Rechallenge may be considered on individual basis with close monitoring upon complete resolution 5

Grade 3 (Severe symptoms, interfering with ADLs):

• Permanently discontinue pembrolizumab 5, 2
• Initiate methylprednisolone 1-2 mg/kg/day IV (or equivalent) 5
• Taper over 6-8 weeks after improvement 5
• If no improvement within 48-72 hours, escalate immunosuppression with: 5, 1
  • Infliximab 5 mg/kg (repeat every 2 weeks if needed) 5
  • Tocilizumab 8 mg/kg 5
  • Mycophenolate mofetil 1 g twice daily 5, 1
  • IVIG 2 g/kg over 2-5 days 5

Grade 4 (Life-threatening):

• Permanently discontinue pembrolizumab 2
• Immediate high-dose IV corticosteroids 5
• Add second-line immunosuppression immediately (do not wait 72 hours) 1
• ICU-level supportive care 5

Grade 5 (Fatal):

• Accounts for 0.22% of all patients and represents the most common cause of ICI-related death 5, 1

Critical Management Pitfalls

Never rechallenge with pembrolizumab after grade 3-4 pneumonitis: In documented series, 2 of 7 patients re-treated developed recurrent pneumonitis. 1

Do not taper steroids too quickly: Recurrent pneumonitis occurs with premature steroid withdrawal, requiring prolonged tapering over 4-8 weeks depending on initial grade. 5, 4

Recognize chronic immune-related pneumonitis: Approximately 2% of patients develop distinct clinicopathological features requiring long-term immunosuppression (≥12 weeks). 5

Monitoring Strategy

Baseline assessment: 5, 6

• Chest imaging before initiating pembrolizumab
• Pulmonary function tests in patients with COPD or pre-existing ILD
• Specialist consultation for patients with pre-existing ILD 5

During treatment: 6

• Patient education about pneumonitis symptoms with instructions for immediate reporting 6
• Heightened surveillance during first 3-6 months (highest risk period) 6
• Any new or worsening respiratory symptoms warrant immediate chest CT 6

Combination Therapy Considerations

Pembrolizumab combined with chemotherapy increases pneumonitis risk with a risk ratio of 2.79 (95% CI 2.09-3.74) compared to chemotherapy alone. 6

When combined with platinum-based chemotherapy, monitor for overlapping toxicities including neutropenia (nadir days 7-14) and cumulative anemia, which may complicate pneumonitis recognition. 6

Prognosis and Recovery

Most patients recover completely with appropriate corticosteroid therapy, particularly those with organizing pneumonia pattern. 9, 4

However, some cases progress to residual or progressive interstitial fibrosis despite prolonged treatment, emphasizing the importance of early recognition and aggressive management. 9

The overall prognosis is relatively good with early detection and adequate steroid therapy, but fatal outcomes occur in approximately 9% of grade 5 cases. 1, 4